DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
Anouk Donners, Konrad van der Zwet, Antoine C G Egberts, Karin Fijnvandraat, Ron Mathôt, Ilmar Kruis, Marjon H Cnossen, Roger Schutgens, Rolf T Urbanus, Kathelijn Fischer*
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A'. Together they form a unique fingerprint.